Dustin Samples

Cancer Nursing Today nonprod

Chronic graft-versus-host disease (cGVHD) can become steroid refractory, so there is a need for second-line therapies to reduce steroid reliance. One previously studied treatment is subcutaneous low-dose (LD) interleukin-2 (IL-2). At the Dana-Farber Cancer Institute, children and adults have previously demonstrated partial responses (PR) to LD IL-2 at approximately 8 weeks.At the 2023 Tandem Meetings of the ASTCT and CIBMTR, researchers from the Dana-Farber Cancer Institute presented their real-world findings of subcutaneous LD IL-2 for children with steroid-refractory cGVHD.From August 2016-July 2022, 15 children with steroid-refractory cGVHD underwent treatment with subcutaneous LD IL-2 (median age, 10.4 years old). All had moderate-severe cGVHD with an average of 2.3 organs involved. The median time from diagnosis to the start of IL-2 therapy was 234 days. Four patients received reduced doses (3 due to malaise and 1 due to thrombocytopenia), and the rest received the institution&rsquo;s previously demonstrated maximum dose of 1x106IU/m2/day. The median time of LD IL-2 treatment was 462 days.No serious adverse events occurred attributable to therapy with LD IL-2. During the study period, 2 patients died (1 due to advanced hepatic dysfunction and 1 due to poor graft function) and the remaining 13 children had an overall response rate of 85% after at least 8 weeks of therapy. There were only 3 children with a complete response, but 8 had a partial response, and 2 others demonstrated stable disease. Of the patients with a partial response, 4 had complete responses specific to 1 or more tissue systems.&ldquo;As expected, Treg expanded preferentially with a peak fold increase in Treg:CD4+ conventional T cell (Tcon) ratio of 2.83 (IQR: 2.55, 5.11) by 2 months on therapy,&rdquo; the authors said. &ldquo;Treg expansion did not appear to be impacted by steroids (median dose at start 0.79mg/kg/d), ruxolitinib (n=2; 10-20mg daily), or calcineurin inhibitors (n=3; standard dosing).&rdquo;Of the 13 evaluable patients, 12 were able to significantly reduce their steroid dose.&ldquo;Our data support a growing body of evidence that LD IL-2 is a safe, well-tolerated, steroid-sparing agent with a high response rate in children, including CRs for cutaneous cGVHD,&rdquo; the researchers concluded.Wobma H, Kapadia M, Calderon FA, et al. Real-World Experience with Low Dose Interleukin-2 for Children with Steroid Refractory Chronic Graft Vs Host Disease. Abstract #347. Presented at the 2023 Tandem Meetings of ASTCT and CIBMTR; February 15-19, 2023; Orlando, FL.

Low-Dose Interleukin-2 for Pediatric Steroid-Refractory Chronic Graft-Versus-Host Disease

Conferences

Low-dose interleukin-2 was safe and well-tolerated as a steroid-sparing agent for pediatric cGVHD.

About Us

Editorial Policy

Authors

Advertising

eNewsletters

Contact Us

Contribute

Calendar of Events

Career Center

Blood Cancers Today

GU Oncology Now

DocWire News

MashupMD

Urban Health Today

Breast Cancer

Colorectal Cancer

GI Cancer

GU Cancer

Gynecologic Cancer Awareness Month

Gyn-Onc

Blood Cancer Awareness Month

GVHD

Leukemia

Lymphoma

Myeloproliferative Neoplasms

Multiple Myeloma

Myelodysplastic Syndrome

Myelofibrosis

Sickle Cell

Hem/Onc

Professional Development

Patient Voice

Lung Cancer

Skin Cancer

Other Tumor Types

News

Treatment

More

Calendar

CARE Award

Best Practices

Expert Interviews

Subscribe